A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia

Detalles Bibliográficos
Autores principales: Kohn, Milena, Delord, Marc, Chbat, Maureen, Guemriche, Amina, Merabet, Fatiha, Roupie, Anne-Laure, Lombion, Naelle, Farhat, Hassan, Longval, Thomas, Cabannes-Hamy, Aurélie, Lambert, Juliette, Marque-Juillet, Stéphanie, Raggueneau, Victoria, Osman, Jennifer, Spentchian, Marc, Rigaudeau, Sophie, Rousselot, Philippe, Besson, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152953/
https://www.ncbi.nlm.nih.gov/pubmed/34788987
http://dx.doi.org/10.3324/haematol.2021.280026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152953/
https://www.ncbi.nlm.nih.gov/pubmed/34788987
http://dx.doi.org/10.3324/haematol.2021.280026

Ejemplares similares